New medication for advanced pancreatic cancer approved
Onivyde® (Nal-Irinotecan) was approved 10/2016 for treatment of advanced pancreatic cancer.
Onivyde® can be used when treatment with Gemcitabine faile. In combination with 5-FU Onivyde® had a positive influence in the course of disease in comparison to 5-FU mono.
Literature: Wang-Gillam A, Li CP, Bodoky G et al.: Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016 Feb 6;387(10018):545-57. doi: 10.1016/S0140-6736(15)00986-1.